T1	Participants 136 200	treatment of recurrent or refractory non small-cell lung cancer.
T2	Participants 932 1055	All patients had histologically confirmed nonsquamous NSCLC that had progressed during or after one platinum-based regimen.
T3	Participants 1064 1091	One hundred twenty patients
